Antiphospholipid Syndrome clinical trials
The registry lists 121 studies for Antiphospholipid Syndrome across more than 10 countries. 52 are recruiting or about to start. 83 of them are mainly about Antiphospholipid Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Antiphospholipid Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Central Hospital, Nancy, France (7) · Centre Hospitalier Universitaire de Nīmes (6) · Assistance Publique - Hôpitaux de Paris (6) · China Immunotech (Beijing) Biotechnology Co., Ltd. (6) · Hospital for Special Surgery, New York (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · New Valley University (3) · Peking University People's Hospital (3)
What is being tested here
Drugs under test in Antiphospholipid Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| YTS109 | 6 | 0 | 6 |
| Enoxaparin | 1 | 0 | 3 |
| Belimumab | 1 | 1 | 2 |
| BRL-301 | 1 | 0 | 1 |
| Anti-CD19 CAR T Cells Preparation | 1 | 0 | 1 |
| Daratumumab | 1 | 0 | 1 |
| Anifrolumab | 1 | 0 | 1 |
| Evarucabgene Autoleucel | 1 | 0 | 1 |
| Zanubrutinib | 1 | 0 | 1 |
| Warfarin | 1 | 0 | 1 |
Drug classes tested here Factor Xa inhibitors 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases · Polina Stepensky
- Nov 2026Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Nov 2026An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Dec 2026Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks · Peking Union Medical College Hospital
- Dec 2026Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome · New Valley University
- Dec 2026The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study · Peking University People's Hospital
- Jan 2027Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome · Chinese University of Hong Kong
- Mar 2027YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases · Children's Hospital of Fudan University
- Mar 2027Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) · Hospital for Special Surgery, New York
- Mar 2027Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) · Chugai Pharmaceutical
Who these studies take
Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger. 5 (13%) take children under 18. 2 (5%) are for women only and 0 (0%) for men only; 5 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (11%) | 4 (11%) |
| 18 | 36 (95%) | 35 (92%) |
| 30 | 36 (95%) | 34 (89%) |
| 40 | 35 (92%) | 34 (89%) |
| 50 | 34 (89%) | 34 (89%) |
| 65 | 34 (89%) | 34 (89%) |
| 75 | 20 (53%) | 20 (53%) |
| 85 | 16 (42%) | 16 (42%) |
Across all 121 studies, recruiting or not: 44% stop at 75 or younger and 31% at 65; 12% take children; 20% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 121. Browse all 121 → or search them.
- Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort StudyRecruitingNCT07757789Not applicable1 country
- Follow-up Cohort of Patients With Antiphospholipid SyndromeRecruitingNCT071789251 country
- An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune DiseaseRecruitingNCT06379646Not applicable1 country
- A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesRecruitingNCT06978647Phase 11 country
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesRecruitingNCT07123519Phase 11 country
- Daratumumab in Primary Antiphospholipid SyndromeRecruitingNCT05671757Phase 1/21 country
- A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07104721Phase 11 country
- Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid SyndromeNot yet recruitingNCT07875153Phase 31 country
- Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune DiseasesRecruitingNCT07301164Early Phase 11 country
- Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune DiseasesRecruitingNCT06828042Phase 1/21 country
- Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune DeficienciesRecruitingNCT072511791 country
- Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid SyndromeRecruitingNCT07743242Not applicable1 country
- Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular ResearchNot yet recruitingNCT07737470
- Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid SyndromeRecruitingNCT071422391 country
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)RecruitingNCT06371417Phase 120 countries
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesRecruitingNCT07087912Phase 41 country
- Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Enrolling by invitationNCT06723106Phase 119 countries
- Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)RecruitingNCT07584083Phase 21 country
- Genetic Risk Factors Associated With Antiphospholipid Antibody SyndromeRecruitingNCT004827941 country
- Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid SyndromeEnrolling by invitationNCT055833051 country
- International Registry of Thrombotic APS Patients Treated With Direct Oral AnticoagulantsRecruitingNCT042624921 country
- Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune DiseasesRecruitingNCT07085676Phase 11 country
- Point of Care Testing INR in Antiphospholipid SyndromeNot yet recruitingNCT07570511Not applicable1 country
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)RecruitingNCT001980683 countries
- An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07236762Phase 11 country
- Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesRecruitingNCT07236801Phase 11 country
- YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT07439029Phase 11 country
- Rheumatology Patient Registry and BiorepositoryRecruitingNCT044020861 country
- Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS PatientsRecruitingNCT073721701 country
- Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune DiseasesRecruitingNCT06614270Not applicable1 country
- A Study of CD19 UCAR-T Cells in Subjects With Autoimmune DiseasesNot yet recruitingNCT07212322Not applicable1 country
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APSRecruitingNCT056463942 countries
- Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally StudyRecruitingNCT006163171 country
- Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)RecruitingNCT07163338Not applicable1 country
- Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid SyndromeRecruitingNCT06373926Not applicable1 country
- Hematological Disorders in EHPVO PatientsNot yet recruitingNCT07108023
- Anti-CD38 Antibody Treating APS With ThrombocytopeniaRecruitingNCT05983952Phase 21 country
- DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort StudyNot yet recruitingNCT068843841 country
- Negative Antiphospholipid Syndrome: a Multicentric StudyRecruitingNCT063730031 country
- OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux DirectsNot yet recruitingNCT069291821 country
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Phase 21 country
- Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 21 country
- Clinical Outcomes of Primary Versus Secondary Antiphospholipid SyndromeNot yet recruitingNCT068086071 country
- Effect of Belimumab on Antibody Titers in Primary APS PatientsRecruitingNCT06747312Phase 21 country
- Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune DiseasesEnrolling by invitationNCT05859997Not applicable1 country
- The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control StudyNot yet recruitingNCT06504420Phase 2
- Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworksRecruitingNCT052300171 country
- The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06420154Early Phase 11 country
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune DiseaseRecruitingNCT06373081Not applicable1 country
- Use of Warfarin After the First Trimester in Pregnant Women With APSRecruitingNCT02303171Phase 41 country